桥梁基因组学和药物流行病学扩大酒精使用障碍治疗选择
medRxiv : the preprint server for health sciences
|January 16, 2026
概括
这项研究开发了一种新的方法,以寻找用于治疗酒精使用障碍 (AUD) 的现有药物. 该方法成功地将巴克洛芬确定为一个有前途的候选人,在真实世界患者数据中显示了减少酒精消费.
科学领域:
- 药物基因组学 药物基因组学
- 计算生物学 计算生物学
- 药学流行病学 药学流行病学
背景情况:
- 酒精使用障碍 (AUD) 是一个重要的公共卫生问题,有效的药物治疗方法有限.
- 药物再利用提供了一种具有成本效益的策略,以发现新的AUD治疗方法.
研究的目的:
- 开发和验证一个综合管道,用于识别和评估AUD的药物重用候选人.
- 为了利用遗传和电子健康记录 (EHR) 数据用于AUD中的药物发现.
主要方法:
- 综合全基因组关联研究 (GWAS) 数据与网络分析,以确定与酒精有关的基因.
- 将已识别的基因映射到FDA批准的药物中,并根据安全性和相关性对候选药物进行过.
- 使用EHR数据进行了药理流行病学分析,以评估巴克洛芬对酒精消费的实际有效性.
主要成果:
- 确定了327个与酒精有关的基因,并将它们与FDA批准的195种药物联系起来.
- 选择了包括巴克洛芬在内的26种候选药物进行进一步评估.
- 现实世界的数据表明,与匹配的对照组相比,巴克洛芬使用与减少酒精消费有关.
结论:
- 开发的管道有效地通过整合基因组和临床数据来识别AUD的有希望的药物重定向候选人.
- 这些发现支持巴克洛芬作为AUD的潜在治疗剂,并需要在临床试验中进一步调查.
- 这种方法可以加速开发用于酒精使用障碍的新药疗法.
更多相关视频
相关概念视频
Drug Abuse and Addiction: Pharmacological Phenomena
1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K
Genome-wide Association Studies-GWAS
15.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.3K
Analysis of Population Pharmacokinetic Data
682
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
682
Human Genetics
1.5K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.5K
Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257


